Cara therapeutics inc.

He has more than 25 years of executive and commercial leadership experience in the pharmaceutical industry. Prior to joining Cara Therapeutics, Eric was the Vice President, Sales and Marketing for Nuvo Research Inc, a specialty pharmaceutical company specializing in topical pain products.CARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ... CARA: The Nasdaq Stock Market LLC: Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) ...Cara Therapeutics Inc’s trailing 12-month revenue is $27.2 million with a -410.9% profit margin. Year-over-year quarterly sales growth most recently was -70.0%. Analysts expect adjusted earnings to reach $-1.998 per share for the current fiscal year. Cara Therapeutics Inc does not currently pay a dividend.In this Annual Report on Form 10-K, the terms “we,” “us” and “our” refer to Cara Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This Annual Report on Form 10-K contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties.0001346830--12-312021Q2false000000000000000000005008816149872213P30DP30D2023-12-312023 …

In this Annual Report on Form 10-K, the terms “we,” “us” and “our” refer to Cara Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This Annual Report on Form 10-K contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial risks and …

C/O CARA THERAPEUTICS, INC. 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL (Street) STAMFORD: CT: 06902 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol Cara Therapeutics, Inc. [ CARA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director:Cara Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT05978063 Other Study ID Numbers: CR845-310601 : First Posted: August 7, 2023 Key Record Dates: Last Update Posted: August 7, 2023 Last Verified: August 2023 Individual ...

See the latest Cara Therapeutics Inc stock price (CARA:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Nov 13, 2023 · STAMFORD, Conn., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the third quarter ended September 30, 2023. Also surging around 60% this year has been marijuana stock Cara Therapeutics (NASDAQ: CARA). However, unlike GWPH, CARA’s rise has all been about the potential for approval.CARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ... CARA: The Nasdaq Stock Market LLC: Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) ...Tracfone Wireless Inc has been a leading player in the telecommunications industry, offering innovative solutions and cutting-edge technology to its customers. With a focus on providing reliable and affordable wireless services, Tracfone ha...

Approval triggers $1.5 million milestone payment to Cara. STAMFORD, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company ...

--Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results ...

Sep 25, 2023 · Approval triggers $1.5 million milestone payment to Cara. STAMFORD, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company ... 6 Degrees. 973-768-2170. [email protected]. INVESTOR CONTACT: Iris Francesconi, Ph.D. Cara Therapeutics. 203-406-3700. [email protected]. Oral presentation will include ...STAMFORD, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ...May 18, 2023 · Cara Therapeutics Contacts: Media Contact Annie Spinetta 6 Degrees M. +1 973-768-2170 ... According to 6 analyst offering 12-month price targets in the last 3 months, Cara Therapeutics has an average price target of $18.17 with a high of $28.00 and a low of $4.00. Below is a summary of ...Jun 30, 2022 · Conference Call & Webcast. Cara management will host a conference call and live webcast today at 8:30 a.m. ET to discuss the positive topline results. To participate in the conference call, please ... C/O CARA THERAPEUTICS, INC. 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL (Street) STAMFORD: CT: 06902 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol Cara Therapeutics, Inc. [ CARA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director:

Head Co-ordination, ONGC; Deendayal Urja Bhawan, 5A, Nelson Mandela Marg, Vasant Kunj, New Delhi-110070; Telephone: 011-26750111 (Office), 011-26129091 (Fax)Nov 2, 2023 · STAMFORD, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ... If you’re an adult on hemodialysis suffering from an intense itch, it may be associated with your chronic kidney disease (CKD). KORSUVA is the first and only FDA-approved treatment specifically designed for this kind of itch. It’s for adults on hemodialysis with moderate-to-severe chronic kidney disease–associated pruritus (CKD-aP).Cara Therapeutics’ loss per share estimates for 2022 have narrowed from $1.49 to $1.47 in the past 30 days. Cara Therapeutics topped earnings estimates in three of the last four quarters ...STAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ...

47.45%. Get the latest Cara Therapeutics Inc (CARA) real-time quote, historical performance, charts, and other financial information to help you make more informed …Party:INC . S/o|D/o|W/o: Late Cheniram Kurmi . Age: 43 . Name Enrolled as Voter in: 101 Mariani (Assam) constituency, at Serial no 912 in Part no 69 . Self Profession:Business …

6 Degrees. 973-768-2170. [email protected]. INVESTOR CONTACT: Iris Francesconi, Ph.D. Cara Therapeutics. 203-406-3700. [email protected]. Oral presentation will include ...Cara Therapeutics 4 Stamford Plaza107 Elm Street, 9th FloorStamford, CT 06902 (203) 406-3700 For information about KORSUVA™ (difelikefalin), or to report an adverse event please call: (844) 835-8277 Contact Us Get in touch and we’ll get back to you as soon as we can. We look forward to hearing from you!Cara Therapeutics, Inc. (CARA) Q2 2023 Earnings Call Transcript SA Transcripts Mon, Aug. 07 Cara Therapeutics GAAP EPS of -$0.58 misses by $0.04, revenue of $6.93M beats by $0.23MCara Therapeutics’ loss per share estimates for 2022 have narrowed from $1.49 to $1.47 in the past 30 days. Cara Therapeutics topped earnings estimates in three of the last four quarters ...Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer . STAMFORD, Conn., Sept. 12, 2022 – Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as …Media Contact Claire LaCagnina 6 Degrees 315-765-1462 [email protected] : Investor Contact Janhavi Mohite Stern Investor Relations, Inc. 212-363-1200May 18, 2023 · Cara Therapeutics Contacts: Media Contact Annie Spinetta 6 Degrees M. +1 973-768-2170 ... 26 Mei 2017 ... Cara Therapeutics is a drug developer that shares a key similarity with Insys Therapeutics: its drug development pipeline isn't entirely devoted ...Cara Therapeutics Inc's market capitalization is $52.10 M by 54.48 M shares outstanding. Is Cara Therapeutics stock a Buy, Sell or Hold? Cara Therapeutics stock has received a consensus rating of buy.Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic ...

Cara Therapeutics contacts: Media Contact Annie Spinetta 6 Degrees 973-768-2170 [email protected]: Investor Contact Iris Francesconi, PhD Cara Therapeutics 203-406-3700 investor ...

About Cara Therapeutics Cara Therapeutics is a close-knit group of scientists, medical experts, and industry leaders deeply committed to the science of changing lives. Our proprietary, novel therapies have the potential to make a significant impact for the millions of pruritus sufferers who have been overlooked.

Nov 29, 2023 · Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most ... Mar 11, 2023 · Following the downgrade, the current consensus from Cara Therapeutics' eight analysts is for revenues of US$53m in 2023 which - if met - would reflect a sizeable 27% increase on its sales over the ... Innovative Drugs Designed to Improve Patients’ Lives Nurix is advancing three internally discovered and wholly owned clinical-stage drug-candidates designed to treat patients with hematologic malignancies and solid tumors. Nurix’s pipeline comprises both Targeted Protein Degraders to eliminate disease causing proteins and E3 ligase inhibitors that …Dec 1, 2023 · Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults ... C/O CARA THERAPEUTICS, INC. 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL (Street) STAMFORD: CT: 06902 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol Cara Therapeutics, Inc. [ CARA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director:29 Apr 2021 ... ... Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed ...In May 2012, Cara Therapeutics Inc and Chong Kun Dang Pharmaceutical Corporation entered into a licens-ing agreement providing the latter with exclusive rights to develop and market difelikefalin in the Republic of Korea [10]. Cara Therapeutics Inc also entered into a license agree-ment with Maruishi Pharmaceutical Company Ltd in AprilVision Statement of Cara Therapeutics, Inc. (CARA) General Overview of Cara Therapeutics, Inc. Cara Therapeutics, Inc. is a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus. The company's lead product candidate, KORSUVA™ (CR845/difelikefalin), is a …Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The company’s novel KORSUVA ...Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q3 2021 Results - Earnings Call Transcript. SA Transcripts Mon, Nov. 08, 2021.STAMFORD, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its licensing partner Maruishi Pharmaceutical Co., Ltd. received manufacturing and marketing approval from Japan’s Ministry of Health, Labour and ...Mar 6, 2023 · Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results. – 4Q22 total revenue was $3.3 million including collaborative revenue of $1.1 million from the Company’s share ...

GALLEN, Switzerland, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics (Nasdaq: CARA) and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA™ (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .The combined company, Vifor Fresenius Medical Care Renal Pharma Ltd., paid Cara $50 million in upfront cash alongside an investment of $20 million in common stock, for global commercialization ...Phone Number +1 203 567 1503. Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Instagram:https://instagram. best stock charting app30year treasury yieldcan i refinance my usda home loancigna plus dental savings plan Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty https://lnkd.in/et_PJv5W Cara Therapeutics Announces up to $40.0 Million Non-Dilutive ...For the third quarter of 2023, net loss was $28.0 million, or $ (0.52) per basic and diluted share, compared to net loss of $23.2 million, or $ (0.43) per basic and diluted share, for the same ... corvette 70th anniversary priceaibax 47.45%. Get the latest Cara Therapeutics Inc (CARA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment... dental insurance plans in tennessee †Cara Therapeutics, Stamford, Connecticut, USA; ‡AplusA Bell Falla, LLC, Newark, New Jersey, USA; and §The Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, NewPhone Number +1 203 567 1503. Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics.